{"pmid":32307014,"title":"Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19.","text":["Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19.","Since December 2019, a novel type of coronavirus disease (COVID-19) in Wuhan led to an outbreak throughout China and the rest of the world. To date, there have been more than 1,260,000 COVID-19 patients, with a mortality rate of approximately 5.44%. Studies have shown that coagulation dysfunction is a major cause of death in patients with severe COVID-19. Therefore, the People's Liberation Army Professional Committee of Critical Care Medicine and Chinese Society on Thrombosis and Hemostasis grouped experts from the frontline of the Wuhan epidemic to come together and develop an expert consensus on diagnosis and treatment of coagulation dysfunction associated with a severe COVID-19 infection. This consensus includes an overview of COVID-19-related coagulation dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy, supportive therapy and prevention. The consensus produced 18 recommendations which are being used to guide clinical work.","Mil Med Res","Song, Jing-Chun","Wang, Gang","Zhang, Wei","Zhang, Yang","Li, Wei-Qin","Zhou, Zhou","32307014"],"abstract":["Since December 2019, a novel type of coronavirus disease (COVID-19) in Wuhan led to an outbreak throughout China and the rest of the world. To date, there have been more than 1,260,000 COVID-19 patients, with a mortality rate of approximately 5.44%. Studies have shown that coagulation dysfunction is a major cause of death in patients with severe COVID-19. Therefore, the People's Liberation Army Professional Committee of Critical Care Medicine and Chinese Society on Thrombosis and Hemostasis grouped experts from the frontline of the Wuhan epidemic to come together and develop an expert consensus on diagnosis and treatment of coagulation dysfunction associated with a severe COVID-19 infection. This consensus includes an overview of COVID-19-related coagulation dysfunction, tests for coagulation, anticoagulation therapy, replacement therapy, supportive therapy and prevention. The consensus produced 18 recommendations which are being used to guide clinical work."],"journal":"Mil Med Res","authors":["Song, Jing-Chun","Wang, Gang","Zhang, Wei","Zhang, Yang","Li, Wei-Qin","Zhou, Zhou"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32307014","week":"202017|Apr 20 - Apr 26","doi":"10.1186/s40779-020-00247-7","keywords":["covid-19","coagulation dysfunction","diagnosis","severe","treatment"],"source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"locations":["Wuhan","China","Chinese","Wuhan","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664632501399715842,"score":8.518259,"similar":[{"pmid":32316065,"title":"Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines.","text":["Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines.","Coronavirus disease 2019 (COVID-19) has caused a global pandemic in just a few months, causing millions infected. Nearly 20% of COVID-19 patients present severe coagulation abnormalities, which may occur in almost all of the severe and critical ill COVID-19 cases. Concomitant venous thromboembolism (VTE), a potential cause of unexplained deaths, has been frequently reported in COVID-19 cases, but its management is still challenging due to the complexity between antithrombotic therapy and coagulation disorders. Based on frontline practical experience and comprehensive literature review, here a panel of experts and physicians from China and Europe developed an evidence and opinion-based consensus on the prophylaxis and management of VTE associated with COVID-19. This statement aims for clinicians treating COVID-19 and provides practical recommendations in detailed situations, for example, how to choose thromboprophylactic measures for patients with diverse severity of disease and bleeding risk, or which kind of anticoagulant should be prescribed. With limited experience on COVID19-associated VTE, this expert consensus statement should be helpful for clinicians worldwide with specific suggestions.","Thromb Haemost","Zhai, Zhenguo","Li, Chenghong","Chen, Yaolong","Gerotziafas, Grigorios","Zhang, Zhenlu","Wan, Jun","Liu, Peng","Elalamy, Ismail","Wang, Chen","32316065"],"abstract":["Coronavirus disease 2019 (COVID-19) has caused a global pandemic in just a few months, causing millions infected. Nearly 20% of COVID-19 patients present severe coagulation abnormalities, which may occur in almost all of the severe and critical ill COVID-19 cases. Concomitant venous thromboembolism (VTE), a potential cause of unexplained deaths, has been frequently reported in COVID-19 cases, but its management is still challenging due to the complexity between antithrombotic therapy and coagulation disorders. Based on frontline practical experience and comprehensive literature review, here a panel of experts and physicians from China and Europe developed an evidence and opinion-based consensus on the prophylaxis and management of VTE associated with COVID-19. This statement aims for clinicians treating COVID-19 and provides practical recommendations in detailed situations, for example, how to choose thromboprophylactic measures for patients with diverse severity of disease and bleeding risk, or which kind of anticoagulant should be prescribed. With limited experience on COVID19-associated VTE, this expert consensus statement should be helpful for clinicians worldwide with specific suggestions."],"journal":"Thromb Haemost","authors":["Zhai, Zhenguo","Li, Chenghong","Chen, Yaolong","Gerotziafas, Grigorios","Zhang, Zhenlu","Wan, Jun","Liu, Peng","Elalamy, Ismail","Wang, Chen"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32316065","week":"202017|Apr 20 - Apr 26","doi":"10.1055/s-0040-1710019","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664714520045551617,"score":372.31213},{"pmid":32333248,"title":"Updated diagnosis, treatment and prevention of COVID-19 in children: experts' consensus statement (condensed version of the second edition).","text":["Updated diagnosis, treatment and prevention of COVID-19 in children: experts' consensus statement (condensed version of the second edition).","In the early February, 2020, we called up an experts' committee with more than 30 Chinese experts from 11 national medical academic organizations to formulate the first edition of consensus statement on diagnosis, treatment and prevention of coronavirus disease 2019 (COVID-19) in children, which has been published in this journal. With accumulated experiences in the diagnosis and treatment of COVID-19 in children, we have updated the consensus statement and released the second edition recently. The current version in English is a condensed version of the second edition of consensus statement on diagnosis, treatment and prevention of COVID-19 in children. In the current version, diagnosis and treatement criteria have been optimized, and early identification of severe and critical cases is highlighted. The early warning indicators for severe pediatric cases have been summarized which is utmost important for clinical practice. This version of experts consensus will be valuable for better prevention, diagnosis and treatment of COVID-19 in children worldwide.","World J Pediatr","Shen, Kun-Ling","Yang, Yong-Hong","Jiang, Rong-Meng","Wang, Tian-You","Zhao, Dong-Chi","Jiang, Yi","Lu, Xiao-Xia","Jin, Run-Ming","Zheng, Yue-Jie","Xu, Bao-Ping","Xie, Zheng-De","Liu, Zhi-Sheng","Li, Xing-Wang","Lin, Li-Kai","Shang, Yun-Xiao","Shu, Sai-Nan","Bai, Yan","Lu, Min","Lu, Gen","Deng, Ji-Kui","Luo, Wan-Jun","Xiong, Li-Juan","Liu, Miao","Cui, Yu-Xia","Ye, Le-Ping","Li, Jia-Fu","Shao, Jian-Bo","Gao, Li-Wei","Wang, Yong-Yan","Wang, Xue-Feng","32333248"],"abstract":["In the early February, 2020, we called up an experts' committee with more than 30 Chinese experts from 11 national medical academic organizations to formulate the first edition of consensus statement on diagnosis, treatment and prevention of coronavirus disease 2019 (COVID-19) in children, which has been published in this journal. With accumulated experiences in the diagnosis and treatment of COVID-19 in children, we have updated the consensus statement and released the second edition recently. The current version in English is a condensed version of the second edition of consensus statement on diagnosis, treatment and prevention of COVID-19 in children. In the current version, diagnosis and treatement criteria have been optimized, and early identification of severe and critical cases is highlighted. The early warning indicators for severe pediatric cases have been summarized which is utmost important for clinical practice. This version of experts consensus will be valuable for better prevention, diagnosis and treatment of COVID-19 in children worldwide."],"journal":"World J Pediatr","authors":["Shen, Kun-Ling","Yang, Yong-Hong","Jiang, Rong-Meng","Wang, Tian-You","Zhao, Dong-Chi","Jiang, Yi","Lu, Xiao-Xia","Jin, Run-Ming","Zheng, Yue-Jie","Xu, Bao-Ping","Xie, Zheng-De","Liu, Zhi-Sheng","Li, Xing-Wang","Lin, Li-Kai","Shang, Yun-Xiao","Shu, Sai-Nan","Bai, Yan","Lu, Min","Lu, Gen","Deng, Ji-Kui","Luo, Wan-Jun","Xiong, Li-Juan","Liu, Miao","Cui, Yu-Xia","Ye, Le-Ping","Li, Jia-Fu","Shao, Jian-Bo","Gao, Li-Wei","Wang, Yong-Yan","Wang, Xue-Feng"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333248","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s12519-020-00362-4","keywords":["covid-19","children","infection","sars-cov-2","treatment"],"source":"PubMed","topics":["Treatment","Diagnosis","Prevention"],"weight":1,"locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1665071049702637568,"score":331.50742},{"pmid":32034659,"title":"Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement.","text":["Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement.","Since the outbreak of 2019 novel coronavirus infection (2019-nCoV) in Wuhan City, China, by January 30, 2020, a total of 9692 confirmed cases and 15,238 suspected cases have been reported around 31 provinces or cities in China. Among the confirmed cases, 1527 were severe cases, 171 had recovered and been discharged at home, and 213 died. And among these cases, a total of 28 children aged from 1 month to 17 years have been reported in China. For standardizing prevention and management of 2019-nCoV infections in children, we called up an experts' committee to formulate this experts' consensus statement. This statement is based on the Novel Coronavirus Infection Pneumonia Diagnosis and Treatment Standards (the fourth edition) (National Health Committee) and other previous diagnosis and treatment strategies for pediatric virus infections. The present consensus statement summarizes current strategies on diagnosis, treatment, and prevention of 2019-nCoV infection in children.","World J Pediatr","Shen, Kunling","Yang, Yonghong","Wang, Tianyou","Zhao, Dongchi","Jiang, Yi","Jin, Runming","Zheng, Yuejie","Xu, Baoping","Xie, Zhengde","Lin, Likai","Shang, Yunxiao","Lu, Xiaoxia","Shu, Sainan","Bai, Yan","Deng, Jikui","Lu, Min","Ye, Leping","Wang, Xuefeng","Wang, Yongyan","Gao, Liwei","32034659"],"abstract":["Since the outbreak of 2019 novel coronavirus infection (2019-nCoV) in Wuhan City, China, by January 30, 2020, a total of 9692 confirmed cases and 15,238 suspected cases have been reported around 31 provinces or cities in China. Among the confirmed cases, 1527 were severe cases, 171 had recovered and been discharged at home, and 213 died. And among these cases, a total of 28 children aged from 1 month to 17 years have been reported in China. For standardizing prevention and management of 2019-nCoV infections in children, we called up an experts' committee to formulate this experts' consensus statement. This statement is based on the Novel Coronavirus Infection Pneumonia Diagnosis and Treatment Standards (the fourth edition) (National Health Committee) and other previous diagnosis and treatment strategies for pediatric virus infections. The present consensus statement summarizes current strategies on diagnosis, treatment, and prevention of 2019-nCoV infection in children."],"journal":"World J Pediatr","authors":["Shen, Kunling","Yang, Yonghong","Wang, Tianyou","Zhao, Dongchi","Jiang, Yi","Jin, Runming","Zheng, Yuejie","Xu, Baoping","Xie, Zhengde","Lin, Likai","Shang, Yunxiao","Lu, Xiaoxia","Shu, Sainan","Bai, Yan","Deng, Jikui","Lu, Min","Ye, Leping","Wang, Xuefeng","Wang, Yongyan","Gao, Liwei"],"date":"2020-02-09T11:00:00Z","year":2020,"_id":"32034659","week":"20206|Feb 03 - Feb 09","doi":"10.1007/s12519-020-00343-7","source":"PubMed","topics":["Treatment","Diagnosis","Prevention"],"weight":1,"locations":["Wuhan","China","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640875339186179,"score":289.58963},{"pmid":32302445,"title":"Reply to \"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy\".","text":["Reply to \"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy\".","We have just read with interest the article recently published in your Journal and titled \"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy\" by Tang N. et al (1). In this article, it is suggested that those patients with COVID-19 that accomplish the Sepsis-Induced Coagulopathy (SIC) criteria, and receive anticoagulant treatment would present a reduction of mortality rates. It is well known that both shock and disseminated intravascular coagulation (DIC) are the two major causes of organ dysfunction in sepsis (2). Furthermore, DIC is a strong predictor of mortality in patients with sepsis, independently of the severity of sepsis (2).","J Thromb Haemost","Coto-Hernandez, Ruben","Fabregas Ruano, Maria Teresa","32302445"],"abstract":["We have just read with interest the article recently published in your Journal and titled \"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy\" by Tang N. et al (1). In this article, it is suggested that those patients with COVID-19 that accomplish the Sepsis-Induced Coagulopathy (SIC) criteria, and receive anticoagulant treatment would present a reduction of mortality rates. It is well known that both shock and disseminated intravascular coagulation (DIC) are the two major causes of organ dysfunction in sepsis (2). Furthermore, DIC is a strong predictor of mortality in patients with sepsis, independently of the severity of sepsis (2)."],"journal":"J Thromb Haemost","authors":["Coto-Hernandez, Ruben","Fabregas Ruano, Maria Teresa"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302445","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14852","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664635401350938627,"score":289.4855},{"pmid":32302456,"title":"Potential of Heparin and Nafamostat Combination Therapy for COVID-19.","text":["Potential of Heparin and Nafamostat Combination Therapy for COVID-19.","Tang et al. recently reported that (Journal of Thrombosis and Haemostasis), in COVID-19 infections caused by the novel coronavirus (SARS-CoV-2), heparin anticoagulant therapy lowers the mortality rate in patients who present with markedly elevated concentrations of D-dimer 1). In other words, abnormal coagulation may influence the prognosis of COVID-19. This is extremely interesting. The article did not describe to what extent heparin improves the abnormal coagulation and further studies by this group are anticipated. The authors reported in that article 1) and a previous article 2) that the abnormal coagulation seen in non-survivors of COVID-19 clearly differs from the abnormal coagulation typically seen in other severe infectious diseases.","J Thromb Haemost","Asakura, Hidesaku","Ogawa, Haruhiko","32302456"],"abstract":["Tang et al. recently reported that (Journal of Thrombosis and Haemostasis), in COVID-19 infections caused by the novel coronavirus (SARS-CoV-2), heparin anticoagulant therapy lowers the mortality rate in patients who present with markedly elevated concentrations of D-dimer 1). In other words, abnormal coagulation may influence the prognosis of COVID-19. This is extremely interesting. The article did not describe to what extent heparin improves the abnormal coagulation and further studies by this group are anticipated. The authors reported in that article 1) and a previous article 2) that the abnormal coagulation seen in non-survivors of COVID-19 clearly differs from the abnormal coagulation typically seen in other severe infectious diseases."],"journal":"J Thromb Haemost","authors":["Asakura, Hidesaku","Ogawa, Haruhiko"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302456","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14858","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["D-dimer","Heparin"],"e_drugs":["Heparin","nafamostat"],"_version_":1664635401218818048,"score":287.95547}]}